Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myriad Genetics ( (MYGN) ) just unveiled an update.
On October 1, 2025, Myriad Genetics entered into a Separation Agreement with its former CFO, Scott J. Leffler, following his departure on August 15, 2025, and official separation on September 2, 2025. The agreement, effective October 9, 2025, includes a severance payment of $1,239,384 and accelerated vesting of equity awards, reflecting the company’s adherence to standard executive transition practices and potentially impacting its financials and leadership dynamics.
The most recent analyst rating on (MYGN) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Myriad Genetics stock, see the MYGN Stock Forecast page.
Spark’s Take on MYGN Stock
According to Spark, TipRanks’ AI Analyst, MYGN is a Neutral.
Myriad Genetics’ overall stock score reflects strong revenue growth and positive earnings call sentiment. However, significant challenges in profitability, cash flow management, and valuation weigh heavily on the score. The technical analysis shows short-term strength, but longer-term indicators suggest caution.
To see Spark’s full report on MYGN stock, click here.
More about Myriad Genetics
Myriad Genetics, Inc. operates in the biotechnology industry, focusing on genetic testing and precision medicine. The company provides diagnostic tests that help assess the risk of developing diseases, guide treatment decisions, and improve patient outcomes.
Average Trading Volume: 1,732,985
Technical Sentiment Signal: Sell
Current Market Cap: $743.4M
Learn more about MYGN stock on TipRanks’ Stock Analysis page.